brands of glp-1 drugs Market Overview: Agonists and the Obesity Market | Blog What are GLP-1 Medications and

The 2023 phase 2 double-blind, randomized controlled trial evaluating a GLP-1/GIP/glucagon receptor triagonist (retatrutide) in patients with the disease of obesity reported 24.2% weight loss at 48 weeks with 12 mg retatrutide

T1DM is defined as an autoimmune disease, resulting in insulin deficiency

Acute pancreatitis In January 2026, the UK MHRA has instructed manufacturers to update the product information for all GLP-1 and dual GIP/GLP-1 receptor agonists to highlight the potential risk of severe acute pancreatitis associated with these drugs, including rare reports of necrotizing and fatal pancreatitis [13]

Researchers at the University of Southern California and others examined the medical records of people taking GLP-1s for their type 2 diabetes

Psychiatry, DOI: 10.4088/JCP.21m14022)

Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should discuss this with their healthcare provider before starting GLP-1 treatment